Obinutuzumab and low-dose steroids for new kidney disease
Part of Heart & circulation, Immune system & allergy, Skin clinical trials.
This study tests a new combination treatment for people newly diagnosed with a type of kidney inflammation linked to ANCA-associated vasculitis. The treatment combines a targeted medication (obinutuzumab) with a low dose of steroids, aiming to control the disease with fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a new diagnosis of ANCA-associated vasculitis (a condition where the immune system attacks small blood vessels), specifically a type called GPA or MPA.
- Your blood test must be positive for one of the ANCA antibodies (called PR3 or MPO).
- Your kidneys must be actively affected, shown by a recent kidney biopsy or by signs of blood and protein in your urine.
- You must not have had prior treatments for this condition with certain medications, such as rituximab, cyclophosphamide, azathioprine, or mycophenolate.
- You must not currently need dialysis or have had dialysis in the past.
- You must not have other serious complications of vasculitis (like bleeding in the lungs, respiratory failure, bowel perforation, or brain involvement), a recent cancer, other autoimmune diseases, active infections, or be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares a new drug (avacopan) with lower doses of steroids to standard steroid treatment for people newly diagnosed with ANCA-associated vasculitis. The goal is to see if avacopan can control your disease with fewer steroid side effects.
This trial tests if adding avacopan to standard treatments (rituximab or cyclophosphamide plus steroids) helps patients with severe kidney inflammation from a type of vasculitis. It may offer a new option for preserving kidney function.
This trial compares two strategies for people with granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA) who have stable disease but whose ANCA blood test has become positive again. The goal is to see whether waiting and monitoring closely works as well as giving a pre-emptive dose of rituximab to prevent a flare.
This trial tests a drug called obinutuzumab to see if it can help people whose vasculitis (inflammation of blood vessels) has come back after previous treatment. It is designed for people with a specific type of vasculitis that affects small blood vessels and is linked to PR3-ANCA antibodies.
This trial tests lower steroid doses for people with certain types of vasculitis that have newly affected their kidneys. The goal is to find out if a lower dose works just as well with fewer side effects.
This trial tests whether obinutuzumab, a targeted therapy that quiets certain immune cells, can reduce kidney damage in people with fibrillary glomerulonephritis. If you have this rare kidney condition and significant protein in your urine, this study may offer a new treatment option.
Hear when a new ANCA-Associated Glomerulonephritis (AAGN) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.